View Exam | PowerPak

1. Which of the following therapies is approved for the treatment of an 11-year-old girl with cystic fibrosis who carries a G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene?

A. Lumacaftor B. Atalauren C. Ivacaftor D. VX-661

2. Based on recent clinical trial findings, which of the following may be the most appropriate treatment option for a patient with cystic fibrosis who is a homozygous F508del carrier?

A. Ataluren and ivacaftor B. Ivacaftor and lumacaftor C. Ivacaftor and VX-661 D. Lumacaftor and VX-661

3. Which of the following did not meet its primary endpoint in a phase 3 clinical trial of patients with a nonsense mutation in the CFTR gene?

A. Ataluren B. Lumacaftor C. Sildenafil D. VX-661

4. Which of the following strategies is appropriate to assess whether an adolescent patient with cystic fibrosis has adhered to therapy while away for college?

A. Reinforce the importance of adherence before entertaining questions B. Use reflective listening C. Ask the patient "Are you taking all of your medications?” D. No assessment is required

5. Which of the following is NOT an appropriate action for a pharmacist to take while managing a patient with cystic fibrosis?

A. Educate healthcare professionals on cystic fibrosis disease B. Participate in multidisciplinary team discussions on cystic fibrosis mediation selection C. Measure lung function throughout the disease continuum D. Counsel patients with cystic fibrosis and their caregivers on methods to improve adherence

Maintenance is scheduled for 08/28/2024 6:00 AM EST - 08/28/2024 5:00 PM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following therapies is approved for the treatment of an 11-year-old girl with cystic fibrosis who carries a G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene?

2. Based on recent clinical trial findings, which of the following may be the most appropriate treatment option for a patient with cystic fibrosis who is a homozygous F508del carrier?

3. Which of the following did not meet its primary endpoint in a phase 3 clinical trial of patients with a nonsense mutation in the CFTR gene?

4. Which of the following strategies is appropriate to assess whether an adolescent patient with cystic fibrosis has adhered to therapy while away for college?

5. Which of the following is NOT an appropriate action for a pharmacist to take while managing a patient with cystic fibrosis?

« Return to Activity

Maintenance is scheduled for 08/28/2024 6:00 AM EST - 08/28/2024 5:00 PM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following therapies is approved for the treatment of an 11-year-old girl with cystic fibrosis who carries a G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene?

2. Based on recent clinical trial findings, which of the following may be the most appropriate treatment option for a patient with cystic fibrosis who is a homozygous F508del carrier?

3. Which of the following did not meet its primary endpoint in a phase 3 clinical trial of patients with a nonsense mutation in the CFTR gene?

4. Which of the following strategies is appropriate to assess whether an adolescent patient with cystic fibrosis has adhered to therapy while away for college?

5. Which of the following is NOT an appropriate action for a pharmacist to take while managing a patient with cystic fibrosis?

« Return to Activity

Customers who Purchased
this Activity also Purchased